Elotuzumab can be combined with other mAbs to increase the activity of effector cells, like the checkpoint inhibitor pembrolizumab (111) to promote tumor-infiltrating NK and CD8+ T-cell activation, intratumoral cytokine and chemokine release (98). Here, CD8A is linked to neoplasm.